Omeprazole — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for GERD (Gastroesophageal Reflux Disease)

• Esomeprazole
• Famotidine
• Lansoprazole
• Pantoprazole
• Ranitidine

Also listed for Peptic Ulcer Disease

• Sucralfate

Also listed for Peptic Ulcer Disease / H. pylori

• Amoxicillin
• Clarithromycin

Other medications in Gastrointestinal

• Azathioprine
• Dapsone
• Dicyclomine
• Hyoscyamine
• Loperamide
• Mesalamine

About Omeprazole

Struggling with persistent heartburn or acid reflux? Omeprazole is a widely prescribed medication known for effectively reducing stomach acid. At TheDrugClub, we believe essential medications should be affordable. Omeprazole is a household name for many who experience the discomfort of acid reflux. As a potent proton pump inhibitor (PPI), it's a cornerstone medication for managing conditions related to excessive stomach acid production. Let's delve into what omeprazole treats, how it works, typical costs, and how TheDrugClub makes it incredibly affordable. ### What Omeprazole Treats

Omeprazole is primarily used to treat conditions caused by too much stomach acid. These include:

• Gastroesophageal Reflux Disease (GERD): Often called chronic acid reflux, GERD causes heartburn, regurgitation, and other symptoms when stomach acid frequently flows back into the esophagus. * Erosive Esophagitis: A more severe form of GERD where the esophagus lining becomes inflamed and damaged by stomach acid. * Stomach Ulcers (Gastric and Duodenal Ulcers): Omeprazole helps heal existing ulcers and prevents new ones by reducing acid that can irritate the stomach lining. * Zollinger-Ellison Syndrome: A rare condition where tumors cause the stomach to produce excessive amounts of acid. * Heartburn: It provides significant relief for frequent heartburn, whether related to GERD or occasional indigestion. ### How Omeprazole Works

Omeprazole belongs to a class of drugs called proton pump inhibitors (PPIs). Its mechanism is quite clever: it works by irreversibly blocking the 'proton pumps' in the cells lining your stomach. These pumps are responsible for the final step in acid secretion. By disabling them, omeprazole effectively reduces the amount of acid produced in

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Omeprazole is approved for (FDA label)

Omeprazole is a proton pump inhibitor (PPI) indicated for the: • Treatment of active duodenal ulcer in adults (1.1) • Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults (1.2) • Treatment of active benign gastric ulcer in adults (1.3) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 2 years of age and older (1.4) • Maintenance of healing of EE due to acid-mediated GERD in patients 2 years of age and older (1.6) • Pathologic hypersecretory conditions in adults (1.7) 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks.

Source: Read the full FDA label on DailyMed. Label effective date: August 28, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Omeprazole (FDA label)

Omeprazole delayed-release capsules USP, 20 mg are off-white to pale yellow, spherical, enteric coated pellets filled in size '2' hard gelatin capsule shells with opaque purple colored cap and opaque grey colored body, imprinted 'OMEPRAZOLE' 20 mg on cap and 'R644' on body with black ink. Omeprazole delayed-release capsules, 20 mg (3)

Source: FDA prescribing information (DailyMed). Set ID: 63b3982a-b541-4b0d-99d4-93a673e57d46. SPL document ID: 5a1de2b5-8ef3-f37b-e063-6394a90ae77e. Label effective date: August 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Omeprazole (FDA label)

The following serious adverse reactions are described below and elsewhere in labeling: • Acute Tubulointerstitial Nephritis [see Warnings and Precautions (5.2) ] • Clostridium difficile -Associated Diarrhea [see Warnings and Precautions (5.3) ] • Bone Fracture [see Warnings and Precautions (5.4) ] • Cutaneous and Systemic Lupus Erythematosus [see Warnings and Precautions (5.6) ] • Cyanocobalamin (Vitamin B-12) Deficiency [see Warnings and Precautions (5.8) ] • Hypomagnesemia and Mineral Metabolism [see Warnings and Precautions (5.9) ] • Fundic Gland Polyps [seeWarnings and Precautions (5.13) ] Adults: Most common adverse reactions in adults (incidence ≥2%) are • Headache, abdominal pain, nausea, diarrhea, vomiting, and flatulence (6) Pediatric patients (2 to 16 years of age): • Safety profile similar to that in adults, except that respiratory system events and fever were the most frequently reported reactions in pediatric studies. (8.4) To report SUSPECTED ADVERSE REACTIONS, contact Dr.

Source: FDA prescribing information (DailyMed). Set ID: 63b3982a-b541-4b0d-99d4-93a673e57d46. SPL document ID: 5a1de2b5-8ef3-f37b-e063-6394a90ae77e. Label effective date: August 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Omeprazole (FDA label)

• Omeprazole delayed-release capsules are contraindicated in patients with known hypersensitivity reactions including anaphylaxis to the formulation or any substituted benzimidazole. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions ( 5.2 ), Adverse Reactions (6) ]. • Proton pump inhibitors (PPIs), including omeprazole, are contraindicated in patients receiving rilpivirine-containing products [see Drug Interactions (7) ]. • For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with omeprazole, refer to the CONTRAINDICATIONS section of their package inserts. • Patients with known hypersensitivity to substituted benzimidazoles or any component of the formulation. (4) • Patients receiving rilpivirine-containing products. ( 4 , 7 ) • Refer to the Contraindications section of the prescribing information for clarithromycin and amoxicillin, when administered in combination with omeprazole. (4)

Source: FDA prescribing information (DailyMed). Set ID: 63b3982a-b541-4b0d-99d4-93a673e57d46. SPL document ID: 5a1de2b5-8ef3-f37b-e063-6394a90ae77e. Label effective date: August 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Omeprazole (FDA label)

Gastric Malignancy: In adults, symptomatic response does not preclude the presence of gastric malignancy.

Source: FDA prescribing information (DailyMed). Set ID: 63b3982a-b541-4b0d-99d4-93a673e57d46. SPL document ID: 5a1de2b5-8ef3-f37b-e063-6394a90ae77e. Label effective date: August 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Omeprazole (FDA label)

Tables 3 and 4 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with omeprazole and instructions for preventing or managing them. Consult the labeling of concomitantly used drugs to obtain further information about interactions with PPIs. Table 3: Clinically Relevant Interactions Affecting Drugs Co-Administered with Omeprazole and Interaction with Diagnostics Antiretrovirals Clinical Impact: The effect of PPIs on antiretroviral drugs is variable. The clinical importance and the mechanisms behind these interactions are not always known.

Source: FDA prescribing information (DailyMed). Set ID: 63b3982a-b541-4b0d-99d4-93a673e57d46. SPL document ID: 5a1de2b5-8ef3-f37b-e063-6394a90ae77e. Label effective date: August 28, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.